NASDAQ
SLS

Sellas Life Sciences Group Inc

Biotechnology
Healthcare

Prices are adjusted according to historical splits.

Sellas Life Sciences Group Inc Stock Price

Vitals

Today's Low:
$1.5
Today's High:
$1.57
Open Price:
$1.54
52W Low:
$1.17
52W High:
$5.58
Prev. Close:
$1.51
Volume:
86374

Company Statistics

Market Cap.:
$42.52 million
Book Value:
0.171
Revenue TTM:
$0
Operating Margin TTM:
0%
Gross Profit TTM:
$900000
Profit Margin:
0%
Return on Assets TTM:
-90.9%
Return on Equity TTM:
-301.93%

Company Profile

Sellas Life Sciences Group Inc had its IPO on 2017-12-29 under the ticker symbol SLS.

The company operates in the Healthcare sector and Biotechnology industry. Sellas Life Sciences Group Inc has a staff strength of 17 employees.

Stock update

Shares of Sellas Life Sciences Group Inc opened at $1.54 at the start of the last trading session i.e. 2023-09-12.

The stocks traded within a range of $1.5 - $1.57, and closed at $1.51.

This is a 0% increase from the previous day's closing price.

A total volume of 86,374 shares were traded at the close of the day’s session.

In the last one week, shares of Sellas Life Sciences Group Inc have increased by +0.67%.

Sellas Life Sciences Group Inc's Key Ratios

Sellas Life Sciences Group Inc has a market cap of $42.52 million, indicating a price to book ratio of 3.7918 and a price to sales ratio of 47.7646.

In the last 12-months Sellas Life Sciences Group Inc’s revenue was $0 with a gross profit of $900000 and an EBITDA of $0. The EBITDA ratio measures Sellas Life Sciences Group Inc's overall financial performance and is widely used to measure its profitability.

In the trailing 12-month period, Sellas Life Sciences Group Inc’s operating margin was 0% while its return on assets stood at -90.9% with a return of equity of -301.93%.

In Q2, Sellas Life Sciences Group Inc’s quarterly earnings growth was a positive 0% while revenue growth was a negative 82.5%.

Sellas Life Sciences Group Inc’s PE and PEG Ratio

Forward PE
0
Trailing PE
0
PEG

Its diluted EPS in the last 12-months stands at $-1.52 per share while it has a forward price to earnings multiple of 0 and a PEG multiple of . A low price to earnings ratio can mean the stock is attractively valued while a high ratio suggests the stock may be overvalued.

The PEG on the other hand provides a broader view compared to the P/E ratio and gives greater insight into Sellas Life Sciences Group Inc’s profitability.

Sellas Life Sciences Group Inc stock is trading at a EV to sales ratio of 27.4527 and a EV to EBITDA ratio of -0.6222. Its price to sales ratio in the trailing 12-months stood at 47.7646.

Sellas Life Sciences Group Inc stock pays annual dividends of $0 per share, indicating a yield of 0% and a payout ratio of 0%.

Balance sheet and cash flow metrics

Total Assets
$18.57 million
Total Liabilities
$13.42 million
Operating Cash Flow
$-2500000.00
Capital Expenditure
$0
Dividend Payout Ratio
0%

Sellas Life Sciences Group Inc ended 2024 with $18.57 million in total assets and $0 in total liabilities. Its intangible assets were valued at $18.57 million while shareholder equity stood at $4.84 million.

Sellas Life Sciences Group Inc ended 2024 with $0 in deferred long-term liabilities, $13.42 million in other current liabilities, 3000.00 in common stock, $-199841000.00 in retained earnings and $1.91 million in goodwill. Its cash balance stood at $13.81 million and cash and short-term investments were $13.81 million. The company’s total short-term debt was $447,000 while long-term debt stood at $0.

Sellas Life Sciences Group Inc’s total current assets stands at $15.58 million while long-term investments were $0 and short-term investments were $0. Its net receivables were $0 compared to accounts payable of $3.73 million and inventory worth $0.

In 2024, Sellas Life Sciences Group Inc's operating cash flow was $-2500000.00 while its capital expenditure stood at $0.

Comparatively, Sellas Life Sciences Group Inc paid $0 in dividends in 2024.

Other key metrics

Current Trading Price
$1.51
52-Week High
$5.58
52-Week Low
$1.17
Analyst Target Price
$6

Sellas Life Sciences Group Inc stock is currently trading at $1.51 per share. It touched a 52-week high of $5.58 and a 52-week low of $5.58. Analysts tracking the stock have a 12-month average target price of $6.

Its 50-day moving average was $1.58 and 200-day moving average was $1.97 The short ratio stood at 9.22 indicating a short percent outstanding of 0%.

Around 20% of the company’s stock are held by insiders while 1803.9% are held by institutions.

Frequently Asked Questions About Sellas Life Sciences Group Inc

The stock symbol (also called stock or share ticker) of Sellas Life Sciences Group Inc is SLS

The IPO of Sellas Life Sciences Group Inc took place on 2017-12-29

Similar Industry Stocks (Biotechnology)

Last Price
Chg
Chg%
$105.7
-1.65
-1.54%
$45
0
0%
$421.35
-9.45
-2.19%
$68
-0.8
-1.16%
Khoobsurat Ltd (KHOOBSURAT)
$1.16
-0.03
-2.52%
$0.26
0.01
+2.48%
$4.18
0.19
+4.76%
$10.74
0.42
+4.07%
$10.93
0.03
+0.28%
$248.33
-1.84
-0.74%

Most Active

Last Price
Chg
Chg%
Amyris Inc (AMRS)
$0.14
0.07
+100%
$0.12
0.04
+45.29%
$0.96
0.05
+5.4%
$1.34
-0.35
-20.71%
Humbl Inc (HMBL)
$0
0
0%

Top Gainers

Last Price
Chg
Chg%
$0
0
+172200%
$0
0
+51200%
$283
280.03
+9428.62%
$11.2
10.57
+1667.68%
Latch Inc (LTCHW)
$0.01
-0.03
+1550%

Top Losers

Last Price
Chg
Chg%
$0.19
-123.15
-99.85%
$0
-0.11
-99.55%
$0
-0
-97.96%
$0
-0.01
-93.94%
$0.01
-0.06
-92.24%

About

SELLAS Life Sciences Group, Inc., a late-stage clinical biopharmaceutical company, focuses on the development of novel cancer immunotherapies for various cancer indications in the United States. The company’s lead product candidate is galinpepimut-S (GPS), a cancer immunotherapeutic agent that targets Wilms tumor 1, which is in Phase 3 clinical trials for the treatment of acute myeloid leukemia; and in Phase 1/2 clinical trials for the treatment for ovarian cancer. It has a strategic collaboration with Merck & Co., Inc. to evaluate GPS as it is administered in combination with PD1 blocker pembrolizumab in a Phase 1/2 clinical trial enrolling patients in up to five cancer indications, including hematologic malignancies and solid tumors; and GenFleet Therapeutics (Shanghai), Inc. for the development and commercialization of GFH009, a highly selective small molecule CDK9 inhibitor, currently under Phase 1 clinical trials. The company is headquartered in New York, New York.

Address

Times Square Tower, New York, NY, United States, 10036